Файловый архив студентов. Файловый архив студентов.
1327 вузов, 5482 предметов.
/ Регистрация
FAQ Обратная связь Вопросы и предложения
Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Ростовский Государственный Медицинский Университет
Предмет:
Медицина общая
Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5186_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
29.08.2026
Размер:
83 Мб
Скачать
☆
►Содержание►
(ICON6):arandomised,double-blind,placebo-controlledphase3trial.Lancet2016;387(10023):1066–1074.
63. Ledermann JA, Embleton AC, Perren T, et al. Overall survival results of ICON6: a trial of chemotherapy and
cediranibinrelapsedovariancancer.JClinOncol2017;35(15Suppl):5506–5506.
64. Liu JF, Barry WT, Birrer M, et al. Combination cediranib and olaparib versus olaparib alone for women with
recurrentplatinum-sensitiveovariancancer:arandomisedphase2study.LancetOncol2014;15(11):1207–1214.
65. LiuJF,BarryWT,BirrerM,etal.Overallsurvivalandupdatedprogression-freesurvivaloutcomesinarandomized
phaseIIstudyofcombinationcediranibandolaparibversusolaparibinrelapsedplatinum-sensitiveovariancancer.Ann Oncol2019;30(4):551–557.
66. Harris PA, Boloor A, Cheung M, et al. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-
pyrimidinyl]amino]-2-methyl-benzenesulfonamide(Pazopanib),anovelandpotentvascularendothelial growthfactor receptorinhibitor.JMedChem2008;51(15):4632–4640.
67. GotinkKJ,VerheulHM.Anti-angiogenictyrosinekinaseinhibitors:whatistheirmechanismofaction?Angiogenesis
2010;13(1):1–14.
68. duBoisA,FloquetA,KimJW,et al. Incorporationofpazopanibinmaintenancetherapyofovarian cancer.JClin
Oncol2014;32(30):3374–3382.
69. Richardson DL, Sill MW, Coleman RL, et al. Paclitaxel with and without pazopanib for persistent or recurrent
ovariancancer:arandomizedclinicaltrial.JAMAOncol2018;4(2):196–202.
70. Benson C, Ray-Coquard I, Sleijfer S, et al. Outcome of uterine sarcoma patients treated with pazopanib: a
retrospectiveanalysisbasedontwoEuropeanOrganisationforResearchandTreatmentofCancer(EORTC)SoftTissue andBoneSarcomaGroup(STBSG)clinicaltrials62043and62072.GynecolOncol2016;142(1):89–94.
71. Nishikawa T, Hasegawa K, Yabuno A, et al. Pazopanib as a second line treatment for uterine and ovarian
carcinosarcoma:asingleinstitutionalstudy.JGynecolOncol2017;28(1):e25.
72. MonkBJ,MasLopezL,ZarbaJJ,etal.PhaseII,open-labelstudyofpazopaniborlapatinibmonotherapycompared
with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol2010;28(22):3562–3569.
73. FaivreS,DemetriG,SargentW,etal.Molecularbasisforsunitinibefficacyandfutureclinicaldevelopment.NatRev
DrugDiscov2007;6(9):734–745.
74. KimDW,JoYS, Jung HS, et al. Anorallyadministeredmultitargettyrosinekinaseinhibitor,SU11248,isa novel
potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006;91(10):4070–4076.
75. Osusky KL, Hallahan DE, Fu A, et al. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell
migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis2004;7(3):225–233.
76. Christensen JG. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-
angiogenicandantitumouractivities.AnnOncol2007;18Suppl10:x3–x10.
77. AlifrangisC,ThorntonA,FotopoulouC,etal.Responsetosunitinib(Sutent)inchemotherapyrefractoryclearcell
ovariancancer.GynecolOncolRep2016;18:42–44.
78. ChanJK,BradyW,MonkBJ,etal.AphaseIIevaluationofsunitinibinthetreatmentofpersistentorrecurrentclear
cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). Gynecol Oncol 2018;150(2):247–252.
79. MackayHJ,TinkerA,WinquistE,etal.AphaseIIstudyofsunitinibinpatientswithlocallyadvancedormetastatic
cervicalcarcinoma:NCICCTGTrialIND.184.GynecolOncol2010;116(2):163–167.
80. Castonguay V, Lheureux S, WelchS, et al. A phase II trial of sunitinib in women with metastatic or recurrent
endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia. Gynecol Oncol 2014;134(2):274–280.
81. WilhelmSM,CarterC,TangL,etal.BAY43–9006exhibitsbroadspectrumoralantitumoractivityandtargetsthe
RAF/MEK/ERKpathwayandreceptortyrosine kinases involvedintumorprogressionandangiogenesis.CancerRes 2004;64(19):7099–7109.
82. Guo T, Agaram NP,WongGC, et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in
gastrointestinalstromaltumor.ClinCancerRes2007;13(16):4874–4881.
83. Matei D, Sill MW, Lankes HA, et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal
carcinomatosis:agynecologiconcologygrouptrial.JClinOncol2011;29(1):69–75.
84. Chekerov R, Hilpert F, Mahner S, et al. Sorafenib plus topotecan versus placebo plus topotecan for platinum-
resistant ovarian cancer(TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol2018;19(9):1247–1258.
85. Nimeiri HS, Oza AM, Morgan RJ, et al. A phase II study of sorafenib in advanced uterine
carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2010;117(1):37–40.
86. IkutaK,YanoS,TrungVT,etal.E7080,a multi-tyrosinekinaseinhibitor,suppressestheprogressionofmalignant
pleuralmesotheliomawithdifferentproangiogenic cytokineproductionprofiles.ClinCancerRes2009;15(23):7229–
7237.
87. SenninoB,McDonaldDM.Controllingescapefromangiogenesisinhibitors.NatRevCancer2012;12(10):699–709.
88. Matsui J, Yamamoto Y, Funahashi Y, et al. E7080, a novel inhibitor that targets multiple kinases, has potent
antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.IntJCancer2008;122(3):664–671.
89. BackesFJ,WeiL,CohnDE,etal.PhaseIevaluationoflenvatinibandweeklypaclitaxelinpatientswithrecurrent
endometrial,ovarian,fallopiantube,orprimaryperitonealcancer.GynecolOncol2019;154:23.
90. MakkerV, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial
cancer:aninterimanalysisofamulticentre,open-label,single-arm,phase2trial.LancetOncol2019;20(5):711–718.
91. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses
tumourgrowthinvivo.Nature1993;362(6423):841–844.
92. WangY,FeiD,VanderlaanM,etal.Biologicalactivityofbevacizumab,ahumanizedanti-VEGFantibodyinvitro.
Angiogenesis2004;7(4):335–345.
93. FalconBL,ChintharlapalliS,UhlikMT,etal.Antagonistantibodiestovascularendothelialgrowthfactorreceptor2
(VEGFR-2)asanti-angiogenicagents.PharmacolTher2016;164:204–225.
94. BergersG,HanahanD.Modesofresistancetoanti-angiogenictherapy.NatRevCancer2008;8(8):592–603.
95. Franco M, Roswall P, Cortez E, et al. Pericytes promote endothelial cell survival through induction of autocrine
VEGF-AsignalingandBcl-wexpression.Blood2011;118(10):2906–2917.
96. FrentzasS,SimoneauE, Bridgeman VL, etal. Vessel co-option mediatesresistanceto anti-angiogenic therapy in
livermetastases.NatMed2016;22(11):1294–1302.
97. Hillen F, Griffioen AW. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev
2007;26(3–4):489–502.
98. Schroeder M, Viezens L, Wellbrock J, et al. Sunitinib treatment reduces tumor growth and limits changes in
microvascularpropertiesafter minor surgicalinterventioninan in vivomodelof secondary breastcancergrowth in bone.JSurgOncol2016;113(5):515–521.
99. Croci DO, Cerliani JP, Dalotto-Moreno T, et al. Glycosylation-dependent lectin-receptor interactions preserve
angiogenesisinanti-VEGFrefractorytumors.Cell2014;156(4):744–758.
enhancegrowth.Nature2010;464(7287):431–435.
upregulation.Nature2010;468(7326):973–977.
throughHGFsecretion.Nature2012;487(7408):500–504.
cancerwithaBRAFV600Emutation.InvestNewDrugs2015;33(6):1267–1270.
mutations.NEnglJMed2015;373(8):726–736.
heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation. Gynecol Oncol Rep 2018;26:41–44.
mutation:acasereport.GynecolOncolRep2019;28:26–28.
patients with recurrent or progressive low-grade serous ovarian or peritoneal adenocarcinoma. Ann Oncol 2019;30(suppl_5):v851–v934.
responseandfailure.Oncogene2010;29(28):4018–4032.
functionoftheretinoblastomapathwayinlivertissueandhepatomacells.Gastroenterology2010;138(5):1920–1930.
inhibitioninovariancancer.ClinCancerRes2011;17(6):1591–1602.
palbociclibinhormonereceptor-positivebreastcancer.NPJBreastCancer2018;4:38.
responsivenessinbreastcancertumorcellsgrowninexplantculture.MolCancerRes2019;17(3):669–675.
associatedantitumoractivityinhumantumorxenografts.MolCancerTher2004;3(11):1427–1438.
4/6.JMedChem2005;48(7):2388–2406.
cancer.NEnglJMed2016;375(18):1738–1748.
either relapsed estrogen receptor (ER)-positive ovarian cancers or relapsed ER-positive endometrial cancers. J Clin
Oncol2019;37(15_suppl):5510–5510.
TranslRes2017;9(4):1667–1679.
classIPI3-kinaseinhibitor.MolCancerTher2012;11(2):317–328.
ClassIPI3Kinhibitor,inpatientswithadvancedsolidtumors.InvestNewDrugs2014;32(4):670–681.
(BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advancedsolidtumors.ClinCancerRes2015;21(4):730–738.
BKM120andtheoralpoly(ADPribose)polymerase(PARP)inhibitorolaparibforthetreatmentofhigh-gradeserous ovarianandbreastcancer.AnnOncol2017;28(3):512–518.
advancedorrecurrentendometrial carcinoma:astratifiedtypeI-typeII studyfromtheGINECOgroup.BrJCancer 2017;116(3):303–309.
cancermodelsdrivenbythePI3Kpathway.MolCancerTher2011;10(12):2426–2436.
thetreatmentofrecurrentorpersistentendometrialcarcinoma(MAGGIEstudy).Cancer2016;122(22):3519–3528.
inhibitor.ClinCancerRes2011;17(10):3193–3203.
gedatolisib(PF-05212384)inpatientswithrecurrentendometrialcancer.GynecolOncol2016;142(1):62–69.
p110alphaandp110deltaactivitiesintumorcelllinesandxenograftmodels.MolCancerTher2013;12(11):2319–2330.
intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non­Hodgkin’slymphomas.AnnOncol2016;27(10):1928–1940.
characterization.JAntibiot(Tokyo)1975;28(10):727–732.
positivehigh-gradeovariancancers.GynecolOncol2017;146(1):64–68.
endometrialcarcinoma.JClinOncol2015;33(8):930–936.
letrozole(EL)orhormonaltherapy(medroxyprogesteroneacetate/tamoxifen,PT)inwomenwithadvanced,persistent orrecurrentendometrialcarcinoma(EC):AGOGFoundationstudy.GynecOncol2018;149:2.
cancer.NEnglJMed2014;371(15):1426–1433.
tumourscanbeovercomewithnovelPI3K-AKT-mTORinhibitors.BrJCancer2016;114(6):650–658.
hepatocellularcarcinomathroughtheactivationofamiR-375/oncogenescircuit.SciRep2019;9(1):11695.
progressionwithprevioussystemictherapies.ClinGenitourinCancer2016;14(2):153–159.
renal cell carcinoma. A systematic review and meta-analysis of literature data. Clin Genitourin Cancer 2015;13(2):137–141.
andtheriskfactorsfornon-infectiouspneumonitisinadvancedrenalcellcarcinoma.IntJClinOncol2015;20(4):790–
795.
ribose)polymerase.Nature2005;434(7035):913–917.
strategy.Nature2005;434(7035):917–921.
sensitivitytopoly(ADP-ribose)polymeraseinhibition.CancerRes2006;66(16):8109–8115.
pseudoobscura.Genetics1946;31:269–290.
Biochemistry1994;33(23):7099–7106.
BiochemJ1999;342(Pt2):249–268.
stateoftheart.BiochemPharmacol2012;84(2):137–146.
nucleosomebindingpropertiesofPARP-1.Cell2004;119(6):803–814.
2004;117(Pt6):815–825.
CurrOpinCellBiol2008;20(3):294–302.
nuclei.JBiolChem1981;256(9):4135–4137.
cellsandhealthybonemarrow.MolCancerRes2019;17(2):409–419.
mutatedcancers.Nature2008;451(7182):1116–1120.
2008;451(7182):1111–1115.
cancer.Oncotarget2017;8(47):83063–83074.
strandbreakrepair.NatRevMolCellBiol2017;18(8):495–506.
andBRCA-mutatedbreastcancers.NatStructMolBiol2010;17(6):688–695.
cells.Nature2016;535(7612):382–387.
inhibitorAZD2281alone and in combinationwithplatinumdrugs. ProcNatl Acad SciU S A 2008;105(44):17079–
17084.
inpaclitaxel-andolaparib-resistantovariancancercells.BrJCancer2016;115(4):431–441.
PARPinhibitors.NatMed2016;22(2):194–201.
622inBRCA1-mutantovariancancer.CellRep2016;14(3):429–439.
JClinInvest2018;128(5):2116–2126.
fromratliverbynicotinamideand5’-methylnicotinamide.BiochimBiophysActa1971;238(1):82–85.
2007;7(5):515–523.
vivo.JBiolChem1989;264(8):4312–4317.
poly(ADP-ribose)polymerase-1inhibitorAG14361.JNatlCancerInst2004;96(1):56–67.
temozolomide(TMZ)inpatients(pts)withadvancedsolidtumors.JClinOncol2005;23(16_suppl):3065–3065.
moleculeinhibitorofPolyADP-RibosePolymerase(PARP),KU-0059436(Ku)inpatients(p)withadvancedtumours. JClinOncol2006;24(18_suppl):3022–3022.
response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390(10106):1949–1961.
BRCA-deficientadvancedovariancancer.JClinOncol2009;27(15_suppl):5500–5500.
BRCA1orBRCA2mutationsandrecurrentovariancancer:aproof-of-concepttrial.Lancet2010;376(9737):245–251.
investigationalpoly(ADP-Ribose)polymeraseinhibitor,incancerpatients.ClinTher2017;39(8):e7–e8.
cancer.NEnglJMed2016;375(22):2154–2164.
2018;29(8):1784–1792.
PARPsuppressionwithfunctionalimpactonDNArepair.EurJCancer2016;69:S123–S124.
DNA.JBiolChem2010;285(11):8054–8060.
(ARIEL2Part1):aninternational,multicentre,open-label,phase2trial.LancetOncol2017;18(1):75–87.
cases.AmJMedSci1893;10:487–511.
recurrentorrefractoryovariancancer:agynecologiconcologygroupstudy.GynecolOncol2001;82(1):7–10.
advancedovariancarcinoma.JClinOncol1988;6(4):689–695.
treatmentofrelapsedovariancancer:apilotstudy.AnticancerRes1991;11(4):1641–1643.
non-Hodgkin’slymphoma:aphaseIIstudy.ClinOncol(RCollRadiol)1995;7(5):300–303.
recombinantinterleukin-2forpersistentovariancancerafterplatinum:twenty-four-hourversus7-dayinfusion.JClin Oncol1997;15(11):3399–3407.
resistantorplatinum-refractoryovariancancer.CancerImmunolImmunother2010;59(2):293–301.
patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res 2002;8(12):3686–3695.
with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma.JTranslMed2007;5:66.
tumorkillinginpatientstreatedwithOvarexmAbB43.13(Ab1).CancerImmunolImmunother1998;46(4):201–212.
with MAb-B43.13–evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. Cancer BiotherRadiopharm2001;16(3):187–203.
advancedovariancancer.JClinOncol2009;27(3):418–425.
oregovomab(O)anti-CA125vaccinationwithcarboplatinpaclitaxel(CP)relativetoCPaloneinfront-linetreatmentof optimallycytoreducedstageIII/IVovariancancer(EOC).JClinOncol2017;35(15_suppl):5536–5536.
folatestoreceptornordoesitalterthepotencyofanti-folatesinvitro.CancerChemotherPharmacol2012;70(1):113–
120.
antagonizingfolatereceptor-alpha.CancerImmun2007;7:6.
farletuzumab,inanovariancancermousemodelismediatedbyantibody-dependentcellularcytotoxicity.CancerBiol Ther2013;14(11):1032–1038.
autophagyinovariancancer.ClinCancerRes2015;21(2):448–459.
efficacyandsafetyofweeklyfarletuzumabincombinationwithcarboplatinandtaxaneinpatientswithovariancancer infirstplatinum-sensitiverelapse.JClinOncol2016;34(19):2271–2278.
Immunity1994;1(5):405–413.
mechanismsandmanipulationintumorimmunotherapy.AnnuRevImmunol2001;19:565–594.
1996;271(5256):1734–1736.
blockade in previouslyvaccinated metastaticmelanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003;100(8):4712–4717.
trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005;23(35):8968–8977.
NEnglJMed2018;378(2):158–168.
immunomodulatoryantibodies.TrendsImmunol2014;35(7):290–298.
lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 2008;105(8):3005–3010.
GynecolOncolResPract2016;3:11.
metastaticorrecurrenthumanpapillomavirus-relatedcervicalcarcinoma.JAMAOncol2018;4(7):e173776.
with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma. J Clin Oncol 2019;37(15_suppl):5582–5582.
withBRCA-deficientrecurrentovariancancer.JClinOncol2017;35(15_suppl):e17052–e17052.
superfamily,uponprogrammedcelldeath.EMBOJ1992;11(11):3887–3895.
Blymphocytes.IntImmunol1996;8(5):765–772.
Immunol2002;169(10):5538–5545.
2008;26:677–704.
motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation.JImmunol2004;173(2):945–954.
infection.JExpMed2006;203(10):2281–2292.
memberleadstonegativeregulationoflymphocyteactivation.JExpMed2000;192(7):1027–1034.
interleukin-10secretion.NatMed1999;5(12):1365–1369.
Immunol2001;2(3):261–268.
withouteffectorfunction.JExpMed1998;188(12):2205–2213.
inhibitorsnivolumabandpembrolizumab.SeminOncol2017;44(2):136–140.
PD-L1.Structure2015;23(12):2341–2348.
Commun2017;8:14369.
immunotherapy.NatCommun2016;7:13354.
antibodypembrolizumab.CellRes2017;27(1):147–150.
patients with rare upper gastrointestinal, neuroendocrine, and gynecological malignancies. J Clin Oncol 2019;37(15_suppl):2570–2570.
ipilimumab in patients with persistent or recurrent ovarian cancer. Presented at the 17th Biennial meeting of the InternationalGynecologicCancerSociety,Kyoto,Japan.AbstractOC11,2018
ProteinCell2018;9(1):135–139.
2017;27(1):151–153.
andmismatchrepairproficientrecurrent/persistentendometrialcancer.JClinOncol2019;37(30):2786–2794.
2017;8(52):90215–90224.
promotion.Science2011;331(6024):1565–1570.
cytolyticactivity.Cell2015;160(1-2):48–61.
melanoma.NEnglJMed2016;375(9):819–829.
definestheefficacyofanti-CTLA-4therapyagainstmelanoma.JExpMed2013;210(9):1695–1710.
microenvironment.Cancers(Basel)2014;6(3):1670–1690.
2019;234(6):7983–7993.
toleranceintumors.NatMed2014;20(6):607–615.
2013;34(3):137–143.
PI3K-Aktpathwayinheadandneckcancer.Oncoimmunology2017;6(1):e1261779.
PD-1.NatImmunol2003;4(7):670–679.
ofalternativeimmunecheckpoints.NatCommun2016;7:10501.
epithelialtumors.Science2018;359(6371):91–97.
PD-L1efficacy.Science2015;350(6264):1084–1089.
intrinsicand-extrinsicfactors.Immunity2016;44(6):1255–1269.
immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. Clin Cancer Res
2011;17(10):3408–3419.
peptidebasedvaccineincancerpatients.JClinImmunol2004;24(5):571–578.
2005;5(8):615–625.
montanideISA-51vaccinationofpatientswithepithelial ovariancancerinhigh-riskfirstremission.ClinCancerRes 2008;14(9):2740–2748.
ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res 2012;18(23):6497–6508.
cancer.CancerImmunolRes2014;2(1):37–49.
cancer.AnnOncol2018;29(suppl_10):x24–x38.
withoutepacadostat(E)inthetreatmentofsubjectswithadvancedrecurrentepithelialovariancancer(DeCidE1trial): Tcellresponsesandtumorinfiltrationcorrelatewithtumorregression.JClinOncol2019;37(15_suppl):5576–5576.
adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2013;2(1):e22664.
safetyandefficacyofdendriticcellimmunotherapyinpatientswithrefractorysolidmalignancies,onsupportivecare. Cytotherapy2014;16(2):234–244.
patientswithrefractorymetastatictumorsthatexpressHER-2/neu.ClinCancerRes2009;15(18):5937–5944.
targetingsynthesizedpeptidesforrecurrentovariancancer.JOvarianRes2014;7:48.
caretherapyinthreeopen-labelrandomizedphase2studiesinwomenwithadvancedstageovariancancer(OC).JClin Oncol2014;32(15_suppl):TPS3134–TPS3134.
epithelialovariancarcinoma(EOC)afterprimarydebulkingsurgery(PDS):interimanalysisofaphase2,open-label, randomized,multicentertrial.JClinOncol2018;36(15_suppl):5509–5509.
expressingNY-ESO-1antigeninovariancancerandmelanomapatients.ProcNatlAcadSciUSA2012;109(15):5797–
5802.
basedvaccinesinpatientswithmetastaticcarcinoma.ClinCancerRes2008;14(10):3060–3069.
Microbiol2015;10(4):583–597.
immunotherapy.FrontCellInfectMicrobiol2014;4:51.
papillomavirus-16 E7 to induce an antitumor response correlates with myeloid dendritic cell function. J Immunol 2004;172(10):6030–6038.
cellsindirectandantigen-specificmanner.FrontCellInfectMicrobiol2017;7:279.
immunotherapy with or without cisplatin in treatment of advanced cervical cancer. Int J Gynecol Cancer 2018;28(4):764–772.
vaccineexpressingmesothelin(CRS-207)foradvancedcancers:phaseIstudiesofsafetyandimmuneinduction.Clin
CancerRes2012;18(3):858–868.
(LandmarkEd)2012;17:670–699.
Science2014;343(6166):1235681.
proteinconjugatevaccine:aphase1trial.IntJCancer2000;87(1):79–85.
recombinantinterleukin-2.JNatlCancerInst1987;79(5):1067–1075.
withhumanpapillomavirus-targetedtumor-infiltratingTcells.JClinOncol2015;33(14):1543–1550.
humanpapillomavirus-associatedepithelialcancers.ClinCancerRes2019;25(5):1486–1493.
infiltratinglymphocytes(LN-145)fortreatmentofrecurrent,metastatic,orpersistentcervicalcarcinoma.JClinOncol 2019;37(15_suppl):2538–2538.
Immunother2017;66(2):259–271.
autologousTcellsexpressingenhancedTCRsspecificforNY-ESO-1inpatientswithrecurrentortreatmentrefractory ovariancancer(NCT01567891).JClinOncol2017;35(15_suppl):TPS3094–TPS3094.
ovariancancer.GynecolOncol2017;145(3):420–425.
receptorswithantibody-typespecificity.ProcNatlAcadSciUSA1989;86(24):10024–10028.
lymphocytes.JExpMed1995;181(5):1653–1659.
andchallenges.JHematolOncol2013;6:47.
deliveryofCAR-engineeredTcells.FrontImmunol2018;9:2268.
patientswithmalignantlymphomaoradvancedsolidtumors.CancerImmunolRes2016;4(3):215–224.
19.
Соседние файлы в папке Библиотека им академика М.И. Перельмана
Помощь Обратная связь Вопросы и предложения Пользовательское соглашение Политика конфиденциальности